Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

NCT01559090 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: MEDI-546
DRUG: MEDI-546
DRUG: MEDI-546

Sponsor

AstraZeneca

Collaborators

[object Object]